Metabolic endotoxemia and diabetes mellitus: A systematic review

Metabolism: Clinical and Experimental

Volumn 68, Issue , 2017, Pages 133-144

  Gomes, Júnia Maria Geraldo ^a   Costa, Jorge de Assis ^b   Alfenas, Rita de Cássia Gonçalves ^b  

^a Campus Rio Pomba   (Brazil)

^b FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

Diabetes mellitus; Endotoxin; Insulin resistance; Lipopolysaccharide; Lipopolysaccharide binding protein

Indexed keywords

ANTIDIABETIC AGENT; ENDOTOXIN; INSULIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; ROSIGLITAZONE; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

AGE; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC PATIENT; DIET; DISEASE EXACERBATION; DRUG EFFECT; ENDOTOXEMIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MACROALBUMINURIA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SMOKING; SYSTEMATIC REVIEW; BLOOD; META ANALYSIS;

ACUTE-PHASE PROTEINS; CARRIER PROTEINS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOTOXEMIA; HUMANS; INSULIN RESISTANCE; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS;

EID: 85007413742     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.12.009     Document Type: Review

References (38)

1. [1] American Diabetes Association, Standards of medical care in diabetes — 2016. Diabetes Care 39 (2016), S1–S108, 10.2337/dc16-S001.
2. [2] Musso, G., Gambino, R., Cassader, M., Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 62 (2011), 361–380, 10.1146/annurev-med-012510-175505.
3. [3] Groschwitz, K.R., Hogan, S.P., Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124 (2009), 3–20, 10.1016/j.jaci.2009.05.038.
4. [4] Cani, P.D., Bibiloni, R., Knauf, C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481, 10.2337/db07-1403.
5. [5] Raetz, C.R., Whitfield, C., Lipopolysaccharide endotoxins. Annu Rev Biochem 71 (2002), 635–700, 10.1146/annurev.biochem.71.110601.135414.
6. [6] Gubern, C., López-Bermejo, A., Biarnés, J., et al. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55 (2006), 216–224, 10.2337/diabetes.55.01.06.db05-1108.
7. [7] Liu, X., Lu, L., Yao, P., et al. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese. Diabetologia 57 (2014), 1834–1841, 10.1007/s00125-014-3288-7.
8. [8] Frazier, T.H., DiBaise, J.K., McClain, C.J., Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 35 (2011), 14S–20S, 10.1177/0148607111413772.
9. [9] Cani, P.D., Amar, J., Iglesias, M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772, 10.2337/db06-1491.
10. [10] Moher, D., Liberati, A., Tetzlaff, J., et al. PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e100097, 10.1371/journal.pmed.1000097.
11. [11] Viswanathan, M., Ansari, M.T., Berkman, N.D., et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality methods guide for comparative effectiveness reviews, AHRQ publication no.12-EHC047-EF.2012. Available at: http://www.effectivehealthcare.ahrq.gov/PMID:22479713, 2012.
12. [12] Viswanathan, M., Berkman, N.D., Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol 65 (2012), 163–178, 10.1016/j.jclinepi. 2011.05.008.
13. [13] Higgins, J.P.T., Altman, D.G., Cochrane handbook for systematic reviews of interventions. Assessing risk of bias in included studies, 2008, Wiley Blackwell, England, 187–241.
14. [14] Creely, S.J., McTernan, P.G., Kusminski, C.M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type2 diabetes. Am J Physiol Endocrinol Metab 292 (2007), E740–E747, 10.1152/ajpendo.00302.2006.
15. [15] Al-Attas, O.S., Al-Daghri, N.M., Al-Rubeaan, K., et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol, 15, 2009, 10.1186/1475-2840-8-20.
16. [16] Devaraj, S., Dasu, M.R., Park, S.H., et al. Increased levels of ligands of toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 52 (2009), 1665–1668, 10.1007/s00125-009-1394-8.
17. [17] Lassenius, M.I., Pietiläinen, K.H., Kaartinen, K., et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34 (2011), 1809–1815, 10.2337/dc10-2197.
18. [18] Okorokov, P.L., Anikhovskaia, I.A., Volkov, I.E., et al. Intestinal endotoxin in induction of type 1 diabetes. Fiziol Cheloveka 37 (2011), 138–141 [PMID: 21542330].
19. [19] Pussinen, P.J., Havulinna, A.S., Lehto, M., et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 34 (2011), 392–397, 10.2337/dc10-1676.
20. [20] Harte, A.L., Varma, M.C., Tripathi, G., et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 35 (2012), 375–382, 10.2337/dc11-1593.
21. [21] Hawkesworth, S., Moore, S.E., Fulford, A.J., et al. Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes, 3, 2013, e83, 10.1038/nutd.2013.24.
22. [22] Peräneva, L., Fogarty, C.L., Pussinen, P.J., et al. Systemic exposure to pseudomonal bacteria: a potential link between type 1 diabetes and chronic inflammation. Acta Diabetol 50 (2013), 351–361, 10.1007/s00592-012-0421-2.
23. [23] Jayashree, B., Bibin, Y.S., Prabhu, D., et al. Increased circulatory concentrations of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388 (2015), 203–210, 10.1007/s11010-013-1911-4.
24. [24] Vergès, B., Duvillard, L., Lagrost, L., et al. Changes in lipoprotein kinetics associated with type 2 diabetes affect the distribution of lipopolysaccharides among lipoproteins. J Clin Endocrinol Metab 99 (2014), E1245–E1253, 10.1210/jc.2013-3463.
25. [25] Al-Disi, D.A., Al-Daghri, N.M., Khan, N., et al. Postprandial effect of a high-fat meal on endotoxemia in Arab women with and without insulin-resistance-related diseases. Nutrients 7 (2015), 6375–6389, 10.3390/nu7085290.
26. [26] Zaman, G.S., Zaman, F., Relationship between postprandial endotoxemia in nonobese postmenopausal women and diabetic nonobese postmenopausal women. J Nat Sci Biol Med 6 (2015), 89–93, 10.4103/0976-9668.149098.
27. [27] Manco, M., Putignani, L., Bottazzo, G.F., Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31 (2010), 817–844, 10.1210/er.2009-0030.
28. [28] Allin, K.H., Nielsen, T., Pedersen, O., Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 172 (2015), R167–R177, 10.1530/EJE-14-0874.
29. [29] Walrand, S., Guillet, C., Boirie, Y., et al. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 76 (2004), 1104–1110, 10.1189/jlb.0104050.
30. [30] Yu, W.K., Li, W.Q., Li, N., et al. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol 9 (2003), 1824–1827, 10.3748/wjg.v9.i8.1824.
31. [31] Torres-Castro, I., Arroyo-Camarena, Ú.D., Martínez-Reyes, C.P., et al. Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose. Immunol Lett 176 (2016), 81–89, 10.1016/j.imlet.2016.06.001.
32. [32] Moreira, A.P., Texeira, T.F., Ferreira, A.B., et al. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108 (2012), 801–809, 10.1017/S0007114512001213.
33. [33] Pajkrt, D., Doran, J.E., Koster, F., et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184 (1996), 1601–1608, 10.1084/jem.184.5.1601.
34. [34] Valipour, M., Evaluation of radiation methods to study potential evapotranspiration of 31 provinces. Meteorol Atmos Phys, 127, 2015, 289, 10.1007/s00703-014-0351-3.
35. [35] Valipour, M., Future of agricultural water management in Africa. Arch Agron Soil Sci 127 (2014), 907–927, 10.1080/03650340.2014.9614333.
36. [36] Ghoshal, S., Witta, J., Zhong, J., et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 50 (2009), 90–97, 10.1194/jlr.M800156-JLR200.
37. [37] Kelly, C.J., Colgan, S.P., Frank, D.N., Of microbes and meals: the health consequences of dietary endotoxemia. Nutr Clin Pract 27 (2012), 215–225, 10.1177/0884533611434934.
38. [38] Amar, J., Burcelin, R., Ruidavets, J.B., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 87 (2008), 1219–1223, 10.2337/dc10-1676.